華鋒股份(002806.SZ):控股股東協議轉讓5.09%股份給雷科卓碩
格隆匯8月2日丨華鋒股份(002806.SZ)公佈,公司於2020年7月31日接到控股股東譚幗英通知,譚幗英於2020年7月30日與雷科卓碩簽署了《股份轉讓協議》,約定譚幗英以協議轉讓方式將其所持896.49萬股公司無限售條件流通股(佔公司總股本的5.09%)轉讓給雷科卓碩。轉讓價格為11元/股,交易金額共計9861.39萬元。
該次權益變動完成後,譚幗英仍持有公司26.41%股份,仍為公司控股股東、實際控制人;雷科卓碩將成為公司持股5%以上股東。該次權益變動不會導致公司控制權發生變化,不會對公司治理結構及持續經營產生影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.